These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 16388250)
1. Withdrawal of rofecoxib - a wake up call for drug safety. Mishra P; Palaian S Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250 [No Abstract] [Full Text] [Related]
2. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data". Luepker RV Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016 [No Abstract] [Full Text] [Related]
3. Don't blame it all on the bogey. Day M BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929 [TBL] [Abstract][Full Text] [Related]
4. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
5. Bringing the FDA's Information to Market. Woloshin S; Schwartz LM Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960 [No Abstract] [Full Text] [Related]
6. [Cyclooxygenase inhibitors: a never ending story?]. Macrì R; Manfredi C G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790 [No Abstract] [Full Text] [Related]
7. Rofecoxib, Merck, and the FDA. Villalba L; Witter J N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745 [No Abstract] [Full Text] [Related]
8. Vioxx's history and the need for better procedures and better testing. Gilhooley M Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218 [No Abstract] [Full Text] [Related]
9. Some key points emerging from the COX-2 controversy. Urquhart J Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723 [No Abstract] [Full Text] [Related]
10. Rofecoxib, Merck, and the FDA. Kim PS; Reicin AS N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342 [No Abstract] [Full Text] [Related]
11. Rofecoxib, Merck, and the FDA. Wolfe MM N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749 [No Abstract] [Full Text] [Related]
12. Drug safety special: the safety catch. Wadman M Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591 [No Abstract] [Full Text] [Related]
13. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs. Roth-Cline MD Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875 [No Abstract] [Full Text] [Related]
14. The NSAID roller coaster: more about rofecoxib. Aronson JK Br J Clin Pharmacol; 2006 Sep; 62(3):257-9. PubMed ID: 16934039 [No Abstract] [Full Text] [Related]
15. Lessons learned after the withdrawal of rofecoxib. Giaquinta D Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801 [No Abstract] [Full Text] [Related]
16. The Vioxx debacle revisited. Manthous CA Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904 [No Abstract] [Full Text] [Related]
17. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]